Addressing global regulatory challenges in rare disease drug development
Enrico Costa(Brigham and Women's Hospital), Steffen Thirstrup(European Medicines Agency), Eveline Trachsel(Swissmedic), Anna M.G. Pasmooij(Medicines Evaluation Board), Kerry J Lee(United States Food and Drug Administration), Julienne Vaillancourt(United States Food and Drug Administration), V. Ajith, Amina Khaldi(Université Libre de Bruxelles), Antonella Isgrò(Italian Medicines Agency), Riccardo Luigetti(European Medicines Agency), Violeta Stoyanova‐Beninska(European Medicines Agency)
Cited by 8
Related Papers
Outrageous prices of orphan drugs: a call for collaboration
|The Lancet|2018|160
The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
|Orphanet Journal of Rare Diseases|2022|51
Efficacy and acceptability of antidepressants on the continuum of depressive experiences in patients with cancer: Systematic review and meta-analysis
|Cancer Treatment Reviews|2015|45
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (<scp>HASTE</scp>): How to meet major health needs at a reasonable cost
|American Journal of Hematology|2020|31
Acute hemolysis by hydroxycloroquine was observed in G6PD-deficient patient with severe COVD-19 related lung injury
|European Journal of Internal Medicine|2020|22